ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

BACKGROUND: Patients with metastatic colorectal cancer whose disease has progressed on oxaliplatin- and irinotecan-containing regimens may benefit from EGFR-inhibiting monoclonal antibodies if they do not contain mutations in the KRAS gene (are “wild type”). It is unknown whether these antibodies, s...

全面介紹

Na minha lista:
書目詳細資料
發表在:BMC Cancer
Main Authors: Segelov, Eva, Waring, Paul, Desai, Jayesh, Wilson, Kate, Gebski, Val, Thavaneswaran, Subotheni, Elez, Elena, Underhill, Craig, Pavlakis, Nick, Chantrill, Lorraine, Nott, Louise, Jefford, Michael, Khasraw, Mustafa, Day, Fiona, Wasan, Harpreet, Ciardiello, Fortunato, Karapetis, Chris, Joubert, Warren, van Hazel, Guy, Haydon, Andrew, Price, Tim, Tejpar, Sabine, Tebbutt, Niall, Shapiro, Jeremy
格式: Artigo
語言:Inglês
出版: BioMed Central 2016
主題:
Study Protocol
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886432/
https://ncbi.nlm.nih.gov/pubmed/27246726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2389-8
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍